BioCentury
ARTICLE | Company News

Afexa, Valeant Pharmaceuticals deal

December 19, 2011 8:00 AM UTC

Valeant completed its acquisition of Afexa for C$0.85 per share, or about C$87.7 million ($85.7 million) (see BioCentury, Nov. 7). ...